A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

abstract：:We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16. The resistance of H69/VP to VP-16 was 9.4-fold that of the parent cell line (H69/P). H69/VP showed cross-resistance to Adriamycin (ADM), (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino) c...

journal_title：Cancer chemotherapy and pharmacology

authors： Minato K,Kanzawa F,Nishio K,Nakagawa K,Fujiwara Y,Saijo N

更新日期：1990-01-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：PURPOSE:Ibrutinib is an orally administered, irreversible Bruton's tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. METHODS:Part 1 used an open-label, two-...

journal_title：Cancer chemotherapy and pharmacology

authors： de Jong J,Hellemans P,Jiao JJ,Huang Y,Mesens S,Sukbuntherng J,Ouellet D

更新日期：2017-12-01 00:00:00

abstract：:The development of nitrosoureas has switched from more lipophilic derivatives to congeners with higher water-solubility, since this property was presumably associated with a decrease in myelosuppression. We have compared the therapeutic efficacy of clinically well-known lipophilic nitrosoureas BCNU, CCNU, and MeCCNU w...

journal_title：Cancer chemotherapy and pharmacology

authors： Osieka R,Glatte P,Pannenbäcker R,Schmidt CG

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:Second-line chemotherapy in patients with metastatic gastric cancer (MGC) pre-treated with cisplatin is not a standard option. We studied a combination of irinotecan, fluorouracil and folates. METHODS:Patients progressive to cisplatin-based chemotherapy were enrolled. Irinotecan 180 mg/m(2), folinic acid 200 m...

journal_title：Cancer chemotherapy and pharmacology

authors： Lorizzo K,Fazio N,Radice D,Boselli S,Ariu L,Zampino MG,Nolè F,Magni E,Ardito R,Minchella I,Rocca A,Di Meglio G,Squadroni M,de Braud F

更新日期：2009-07-01 00:00:00

abstract：PURPOSE:This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. METHODS:A modified accelerated titration design was used. 2DG was administe...

journal_title：Cancer chemotherapy and pharmacology

authors： Raez LE,Papadopoulos K,Ricart AD,Chiorean EG,Dipaola RS,Stein MN,Rocha Lima CM,Schlesselman JJ,Tolba K,Langmuir VK,Kroll S,Jung DT,Kurtoglu M,Rosenblatt J,Lampidis TJ

更新日期：2013-02-01 00:00:00

abstract：:The antimetabolite 1-beta-D-arabinofuranosyl-cytosine (ara-C) has proven to be one of the most effective agents available for the treatment of acute leukemia. While ara-C has been implicated as a potent inhibitor of mammalian cell DNA replication, the specific mechanism by which ara-C kills cells is not known. In this...

journal_title：Cancer chemotherapy and pharmacology

authors： Wills P,Hickey R,Ross D,Cuddy D,Malkas L

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Firvida JL,Castro J,Madroñal C,Rodríguez-Jaráiz A,Salgado M,Belda-Iniesta C,Casado E,García-Mata J,González-Barón M,Oncopaz Cooperative Group.

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-mutated cancer. This Phase I, open-label, three-part study (Parts A-C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of olaparib when administered in tablet formulation. METHODS:PK d...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Swaisland H,Leunen K,van Herpen CM,Jerusalem G,De Grève J,Lolkema MP,Soetekouw P,Mau-Sørensen M,Nielsen D,Spicer J,Fielding A,So K,Bannister W,Molife LR

更新日期：2015-10-01 00:00:00

abstract：PURPOSE:Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. METHODS:Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flav...

journal_title：Cancer chemotherapy and pharmacology

authors： Hofmeister CC,Poi M,Bowers MA,Zhao W,Phelps MA,Benson DM,Kraut EH,Farag S,Efebera YA,Sexton J,Lin TS,Grever M,Byrd JC

更新日期：2014-02-01 00:00:00

abstract：:We reviewed 139 resected patients with hepatocellular carcinoma at our clinic between 1963 and 1987, and using the 118 cases for the period between 1963 and 1986, we analyzed the prognostic factors that influenced the long-term prognosis by comparing the survival curves. Significant differences in the survival pattern...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawano N,Ohmori Y,Inoue S,Nagao T,Morioka Y

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:Multidrug resistance (MDR) is known as a problem limiting the success of therapy in patients treated long term with chemotherapeutic drugs. The drug resistance is mainly due to the overexpression of the 170 kDa P-glycoprotein (Pgp), which causes a reduction in drug accumulation in the cancer cells. In this stud...

journal_title：Cancer chemotherapy and pharmacology

authors： Limtrakul P,Khantamat O,Pintha K

更新日期：2004-12-01 00:00:00

abstract：PURPOSE:Valproic acid (VPA), a widely used antiepileptic, also inhibits histone deacetylase (HDAC), and is undergoing evaluation as an anti-cancer agent. We studied the pharmacokinetics of VPA in the plasma and cerebrospinal fluid (CSF) in a non-human primate model that is highly predictive of human CSF penetration to ...

journal_title：Cancer chemotherapy and pharmacology

authors： Stapleton SL,Thompson PA,Ou CN,Berg SL,McGuffey L,Gibson B,Blaney SM

更新日期：2008-04-01 00:00:00

abstract：PURPOSE:To determine the safety, the maximal tolerated dose, and to assess for any clinical activity of pomalidomide given to patients with advanced solid tumors. PATIENTS AND METHODS:Patients with incurable solid tumors were enrolled. Two different dosing schedules were explored. In Cohort A patients were given pomal...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Nock C,Bokar J,Krishnamurthi S,Gibbons J,Rodal MB,Ness A,Remick SC,Dreicer R,Dowlati A

更新日期：2012-11-01 00:00:00

abstract：:Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby research efforts are direct...

journal_title：Cancer chemotherapy and pharmacology

authors： Hausheer FH,Kochat H,Parker AR,Ding D,Yao S,Hamilton SE,Petluru PN,Leverett BD,Bain SH,Saxe JD

更新日期：2003-07-01 00:00:00

abstract：:The selective Aurora-A kinase inhibitor MLN8237 is in clinical trials for hematologic malignancies, ovarian cancer and other solid tumors. We previously showed that MLN8237 is potently antiproliferative toward standard monolayer-cultured glioblastoma cells. We have now investigated the effect of MLN8237 with and witho...

journal_title：Cancer chemotherapy and pharmacology

authors： Hong X,O'Donnell JP,Salazar CR,Van Brocklyn JR,Barnett KD,Pearl DK,deCarvalho AC,Ecsedy JA,Brown SL,Mikkelsen T,Lehman NL

更新日期：2014-05-01 00:00:00

abstract：PURPOSE:An isolated pelvic perfusion technique using multiple agents was used both in patients with unresectable recurrent pelvic neoplasms and as a preoperative therapy for advanced pelvic malignancy. METHODS:The technique consisted of vascular occlusion via transfemoral balloon catheters, circulation and drug infusi...

journal_title：Cancer chemotherapy and pharmacology

authors： Wanebo HJ,Belliveau JF

更新日期：1999-01-01 00:00:00

abstract：:Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

journal_title：Cancer chemotherapy and pharmacology

authors： Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Adam de Beaumais T,Dervieux T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

更新日期：2010-09-01 00:00:00

abstract：:Thirty-three patients with advanced transitional cell carcinoma of the urinary tract (23 bladder cases, 8 ureter cases, and 2 renal pelvis cases) were treated by three-drug combination chemotherapy using two protocols (protocol I: Adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 500 mg/m2, protocol ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kotake T,Usami M,Miki T,Kuroda M,Obata K,Osafune M,Fujioka H,Takasugi Y

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue ag...

journal_title：Cancer chemotherapy and pharmacology

authors： Schroeder PE,Jensen PB,Sehested M,Hofland KF,Langer SW,Hasinoff BB

更新日期：2003-08-01 00:00:00

abstract：:Unfortunately, the online published article has error in Figure 4. The correct Figure 4 is given here. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Q,Li XT,Chen Y,Chen JQ,Zhu JY,Meng Y,Wang XQ,Li Y,Geng SS,Xie CF,Wu JS,Zhong CY,Han HY

更新日期：2018-06-01 00:00:00

abstract：:The effects of heat on intracellular accumulation of anthracyclines were investigated by laser flow cytometry analysis. Sarcoma-180 cells were exposed to Adriamycin (ADM), epirubicin (EPIR), daunomycin (DM), THP-Adriamycin (THP), ME-2303 (ME) and KRN-8602 (KRN) at 37 degrees C and at higher temperatures. There was a d...

journal_title：Cancer chemotherapy and pharmacology

authors： Sakaguchi Y,Maehara Y,Inutsuka S,Takahashi I,Yoshida M,Emi Y,Baba H,Sugimachi K

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:To investigate whether coadministration of vindesine is a risk factor for acute kidney injury caused by high-dose methotrexate in patients with hematologic malignancies and identify its mechanism. METHODS:A retrospective analysis was conducted on 211 cycles of HD-MTX therapy in 178 patients with hematological ...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Xia F,Xue L,Liu L,Bian Y,Jin Z,Miao L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Chang Z,Liu Z

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVES:To assess the cardiovascular safety, tolerability and efficacy of high doses of granisetron for the treatment of nausea and vomiting in patients undergoing highly emetogenic chemotherapy. METHODS:Patients with histologically confirmed malignant disease were given an intravenous infusion of granisetron, 160 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Carmichael J,Harris AL

更新日期：2004-02-01 00:00:00

abstract：:Isothiocyanate sulforaphane (SFN) is a potent cancer chemopreventive agent. We investigated the mechanisms underlying the anti-proliferative effects of SFN in the human colon carcinoma cell line, HT-29. We demonstrate that SFN inhibits the growth of HT-29 cells in a dose- and time-dependent manner. Treatment of serum-...

journal_title：Cancer chemotherapy and pharmacology

authors： Shen G,Xu C,Chen C,Hebbar V,Kong AN

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:Oxaliplatin and satraplatin demonstrate activity against cisplatin-resistant tumor cells. Although the two platinum analogs are structurally-related, oxaliplatin is more active. Therefore, studies focusing on protein expression profiling were undertaken to identify the molecular mechanism for the difference in ...

journal_title：Cancer chemotherapy and pharmacology

authors： He G,Xie X,Siddik ZH

更新日期：2020-06-01 00:00:00

abstract：:Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essential for this activity. We performed a pharmacokinetics study as part ...

journal_title：Cancer chemotherapy and pharmacology

authors： van Warmerdam LJ,Creemers GJ,Rodenhuis S,Rosing H,de Boer-Dennert M,Schellens JH,ten Bokkel Huinink WW,Davies BE,Maes RA,Verweij J,Beijnen JH

更新日期：1996-01-01 00:00:00

abstract：:Taxol is the prototype of a class of antineoplastic drugs that target microtubules. It enhances tubulin-monomer polymerization and stabilizes tubulin polymers, increasing the fraction of cells in the G2 or M phase of the cell cycle. We report that treatment of HL-60 and U937 myeloid cell lines with 1-10 microM taxol i...

journal_title：Cancer chemotherapy and pharmacology

authors： Gangemi RM,Tiso M,Marchetti C,Severi AB,Fabbi M

更新日期：1995-01-01 00:00:00